Anzeige
Erschienen in:
13.11.2017 | Original Article
Robotic-assisted multivisceral resection for rectal cancer: short-term outcomes at a single center
Erschienen in: Techniques in Coloproctology | Ausgabe 11/2017
Einloggen, um Zugang zu erhaltenAbstract
Background
The safety and feasibility of robotic-assisted multivisceral resection for locally advanced rectal cancer remain unclear. The aim of this study was to assess the short-term outcomes of this procedure at our institution.
Methods
From December 2011 to December 2016, patients who underwent robotic-assisted multivisceral resection for rectal cancer were investigated. Patient demographics, treatment characteristics, perioperative outcomes, and pathological results were evaluated retrospectively.
Results
There were 31 patients; 17 men (54.8%) and 14 women (45.2%), with a median age of 65 years (range 40–82 years). Twenty-one patients (67.7%) had a cT4 tumor, 9 patients (29.0%) had a pT4b tumor, and all patients except one (96.8%) underwent complete resection of the primary tumor with negative resection margins. Eleven patients (35.5%) received neoadjuvant chemoradiation. The most commonly resected organ was the vaginal wall (n = 12, 38.7%), followed by the prostate (n = 10, 32.3%). Lateral lymph node dissection was performed in 20 patients (64.5%). The median operative time was 394 min (range 189–549 min), and the median blood loss was 41 mL (range 0–502 mL). None of the patients received intraoperative blood transfusions or required conversion to open. Overall, postoperative complications occurred in 11 patients (35.5%). The most frequent complication was urinary retention (n = 5, 16.1%), and none of the patients developed serious complications classified as Clavien–Dindo grades III–V.
Conclusions
Robotic-assisted multivisceral resection for rectal cancer is safe and technically feasible.